SARS-CoV2 (COVID-19) Seroepidemiological Transplanted Subjects (Kidney, Kidney-pancreas, Pancreas, Langerhans Islets)
- Conditions
- Kidney TransplantPancreatic TransplatPancreatic Islets Langerhans
- Registration Number
- NCT04487197
- Lead Sponsor
- Antonio Secchi
- Brief Summary
Evaluate SARS-CoV2 infection and the degree of immunity possibly developed in transplanted population using the Luciferase Immuno Precipitation System (LIPS) test.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 282
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum-prevalence of COVID-19 / Age, Gender, Type of transplantation, comorbities, Italian regions-proviences transplanted patients From 15 July 2020 to 15 January 2021 Correlation serum-prevalence of COVID-19 / Age, Gender, Type of transplantation, comorbities, Italian regions-proviences transplanted patients
Serum-prevalence of COVID-19 TX From 15 July 2020 to 15 January 2021 Evaluation of serum-prevalence data transplanted patients (symptomatic vs asymptomatic patients)
- Secondary Outcome Measures
Name Time Method Risk factors for infection COVID-19 transplanted patients From 15 July 2020 to 15 January 2021 Determine risk factors for infection COVID-19 (comparison symtomatic and asymtomatic transplanted patients)
Hospitalization rate COVID-19 transplanted patients From 15 July 2020 to 15 January 2021 Evaluate hospitalization rate in transplanted patients
Asymptomatic or subclinical infections in transplanted patients From 15 July 2020 to 15 January 2021 Determine % Asymptomatic or subclinical infections in transplanted patients
Mortality rate COVID-19 transplanted patients From 15 July 2020 to 15 January 2021 Evaluate mortality rate in transplanted patients
Trial Locations
- Locations (1)
IRCCS San Raffaele
🇮🇹Milan, Italy
IRCCS San Raffaele🇮🇹Milan, Italy